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Results: From 1996 to 2004, 38 consecutive pts (median age 61 
(42-77), PS 0-1: 92%, 2-3: 8%) were treated. 84% pts received 4 CT 
cycles and 86% pts full thoracic XRT; 26 pts underwent PCI. Objec-
tive response rate is 84% with 53% CR. With a median follow-up of 26 
months, median disease-free survival, median survival and 5-year sur-
vival rate are respectively 10,6 months [7,3-15,3], 17,6 months [11,0-
31,7] and 29%. Intrathoracic inﬁeld and brain isolated failures occurred 
in respectively in 30% and 22% pts. Main toxicities were neutropenia 
(55% grade 4 neutropenia with 4 deaths due to febrile neutropenia con-
cerning PS 2-3 and elderly pts) and esophagitis (29% grade 3+). Grade 
2+ radiation pneumonitis occurred in 5% of pts.
Conclusion: High dose QD XRT given concurrently with EP CT is 
feasible but must be restricted to good PS patients. Esophagitis remains 
a limiting toxicity. In spite of broad inclusion criteria (no limit of age, 
PS 2-3), median and 5-year survival rate are similar to those reported 
by Turrisi et al. NEJM, 340(4)265-271,1999. These results justify the 
CONVERT phase III study wich will compare QD high dose XRT (66 
Gy) to BID thoracic XRT (45 Gy) given concurrently with EP CT in 
limited-stage SCLC.
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Purpose: To determine the long-term treatment results of hyperfrac-
tionated thoracic radiotherapy with concurrent chemotherapy for clini-
cally diagnosed LD-SCLC patients.
Materials and Methods: Between 1996 and 2004, 46 patients with 
histologically conﬁrmed SCLC were diagnosed with limited-stage 
disease using physical and radiological examinations. Patient character-
istics. Gender: M/F=36/10. Median age: 64 years (21-82), Performance 
status: 0/1/2=13/30/3, T1/2/3/4=8/11/7/20, N0/1/2/3=3/5/25/13, Clini-
cal stage: 2A/2B/3A/3B=1/4/17/24. For chemotherapy, dose-intensive 
(DI) regimens such as CODE and CAV containing doxorubicin were 
preferably used as a neoadjuvant setting before 1998, and, combina-
tions of cisplatin or carboplatin with etoposide or CPT-11 (PE/CPT) 
were used after 1998. Twice-daily thoracic radiotherapy was performed 
with 6/10 MV- X rays with at least a 6-hour interval and total dose was 
45 Gy/1.5 Gy bid in 3 weeks. Radiotherapy was started on day 1 im-
mediately after the 1st/2nd/3rd/4th cycle of chemotherapy (cisplatin: 80 
mg/m2 i.v. on day 0 and etoposide: 100 mg/m2 p.o.) in 18/13/3/12 pts, 
respectively. Primary lesions and enlarged lymph nodes with ipsilateral 
hilum and mediastimum (also with supraclavicular region, when neces-
sary) were covered with AP portals of 30 Gy, then gross tumor volumes 
were irradiated with oblique portals of 15 Gy. A prophylactic cranial 
irradiation (PCI) of 24-30 Gy/2.0-2.5 Gy was used in selected cases. 
Local tumor responses were assessed by RECIST. Survical results were 
analysed by the Kaplan-Meier method. Treatment-related toxicities 
were evaluated according to the CTCAE v3.0.
Results: All of the patients could successfully receive 45 Gy of ir-
radiation. Four cycles of scheduled chemotherapy mostly at a 3-week 
interval were completed in 41 out of 46 patients (89%). This combined 
treatment resulted in an overall response rate of 98%, including 59% 
(27/46) complete responses. Loco-regional recurrences were detected 
on follow-up CT scans in 27% (12/46) of cases, all of which were 
detected within gross tumor volumes at the time of treatment plan-
ning. No clinical/treatment factors were signiﬁcantly correlated to 
local recurrence. Distant metastasis were found in 67% (30/46), and 
the most frequent site of ﬁrst metastasis was brain (39%), while PCI 
were done in 33% (15/46). Overall 46% of the patients were diagnosed 
with brain metastases at some time and subsequently treated by a pal-
liative radiotherapy. For all patients, the median survival time (MST) 
was 22.7 months and the 2/3/5 year survival rates were 44/32/22%. 
The group of the patients treated with standard PE/CPT showed better 
survival than that with DI regimens. (p<0.05; Wilcoxon). With standard 
PE/CPT, MST was 28.6 months and the 2/3/5/ year survival rates were 
51/32/24%. Timing of radiation and chemotherapy, use of PCI did not 
signiﬁcantly impact on survivals in this study. The major toxicities 
included grade 3 and 4 acute neutropenia (15% and 64%, respectively), 
grade 2 and 3 radiation esophagitis (24% and 4%). Radiation pneu-
monitis were observed as grade 2 and 3 in 7% and 13%, respectively, 
and one patient died from severe radiation pneumonia and subsequent 
infectious events. 
Conclusions: Hyperfractionated radiation with concurrent chemothera-
py was well tolerated and showed favorable responses and survivals in 
patients with LD-SCLC. Standard PE/CPT showed a superior survival 
rate to DI regimens. For further improvement of clinical results for 
LD-SCLC, more effective means of prophylaxis/treatment against brain 
metastasis should be established.
